Shopping Cart
- Remove All
- Your shopping cart is currently empty
SEP-363856 (SEP-856) mesylate is an orally active compound that acts as an agonist for both TAAR1 and 5-HT1A receptors. This compound exhibits antipsychotic activity in the central nervous system and has potential for the study of schizophrenia.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | SEP-363856 (SEP-856) mesylate is an orally active compound that acts as an agonist for both TAAR1 and 5-HT1A receptors. This compound exhibits antipsychotic activity in the central nervous system and has potential for the study of schizophrenia. |
Targets&IC50 | 5-HT1D Receptor:0.262 μM (EC50), 5-HT2A Receptor:>10 μM (EC50), 5-HT1A Receptor:2.3 μM (EC50, TAAR1:0.14 μM (EC50), 5-HT7 Receptor:6.7 μM (EC50), 5-HT1B Receptor:15.6 μM (EC50), 5-HT2C Receptor:30 μM (EC50) |
In vitro | SEP-856 mesylate (10 μM) demonstrates greater than 50% inhibition of specific binding at several receptors, including α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7. |
In vivo | SEP-856 mesylate, administered intraperitoneally (0.3, 1, and 10 mg/kg), demonstrates CNS activity and a behavioral profile akin to established antipsychotic medications. When given orally (0.3, 1, and 10 mg/kg, once), SEP-856 mesylate notably diminishes PCP-induced hyperactivity. Additionally, oral dosage of SEP-856 mesylate (1, 3, and 10 mg/kg) leads to a dose-dependent reduction in REM sleep, prolongation in the latency period to REM sleep, and an extension in cumulative wake (W) time. |
Alias | SEP-856 mesylate |
Molecular Weight | 279.38 |
Formula | C10H17NO4S2 |
Cas No. | 2375116-27-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.